Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
Read the full story
This is a short summary. The complete article is published by CNBC.
Continue at CNBC

Headline and summary aggregated from public news feeds. For information only — not financial advice.